Efficacy of Favipiravir Against Severe Ebola Virus Disease

NCT02662855 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
77
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Beijing Institute of Pharmacology and Toxicology

Collaborators